Cannabinol Medicine Dedicated to Conquering Heart Failure

A clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease.

COVID-19 and CVD

Cardiol has been approved by the FDA for a Phase II/III clinical trial to test the efficacy of CardiolRx™ in improving outcomes for COVID-19 patients with cardiovascular disease (CVD).

Learn More

Acute Myocarditis

Cardiol is planning a Phase II international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.

Learn More

Heart Failure

Committed to conquering a serious condition that affects more than 26 million people globally.

Learn More

Latest News

All News

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis

TSX:CRDL NASDAQ:CRDL

Sign up to receive the latest news from Cardiol Therapeutics

© 2023 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy